Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 9 of 11
Feb 12, 2026This post explores the recent $210 million funding round for Talkiatry aiming to leverage AI for patient engagement, alongside Big Health's $24 million raise that underscores renewed investor optimism in digital therapeutics. Additionally, insights into the reassessment of the Apple Watch hypertension feature provide a backdrop for innovations in health technology.
Dr. Alex Morgan
Feb 10, 2026The healthcare startup Solace Health has become a unicorn, valued at over $1 billion after a significant funding round. Its unique approach eliminates the traditional burden on patients by proactively handling scheduling, insurance, and care coordination.
Michael Torres
Feb 6, 2026The biotechnology sector has witnessed a notable resurgence in initial public offerings (IPOs) with Eikon Therapeutics leading the way by raising $381 million to fund clinical trials for cancer immunotherapy. This development may influence market dynamics and investor sentiment within the sector.
Michael Torres
Feb 6, 2026In 2026, the digital health sector sees accelerated consolidation as companies strive to grow and innovate in a competitive landscape shaped by payer and investor pressures. Artificial intelligence emerges as a pivotal factor influencing deal-making and strategic integration within the industry.
Michael Torres
Feb 5, 2026PrimeGen’s decision to go public via a Special Purpose Acquisition Company (SPAC) represents an important step in the evolving regenerative medicine landscape. This strategic move not only provides capital for advancing a promising pre-clinical stem cell pipeline but also highlights growing investor interest in transformative cell therapies targeting unmet medical needs.
Dr. Priya Nandakumar
Feb 4, 2026The year 2021 marked an unprecedented wave of biotech initial public offerings, heavily influenced by pandemic-related funding surges. This article analyzes where these companies stand today, their challenges, and implications for future biotech investment landscapes.
Dr. Priya Nandakumar
Feb 3, 2026The biotech sector is encountering a notably active week for IPOs with four companies navigating toward public listings despite governmental operational interruptions. This development illustrates both market demand for innovative healthcare solutions and the strategic approaches companies adopt to overcome regulatory obstacles in pursuit of capital markets.
Dr. Priya Nandakumar
Feb 2, 2026The prominence of women’s health in the healthcare ecosystem has surged, propelled by specialized technologies and robust investment activity. This article delves into the factors underpinning this sector’s scalability and the regulatory frameworks shaping its development.
Jonathan Blake
Feb 1, 2026This merger brings together two major players in the healthcare industry to offer integrated primary care, behavioral health, pharmacy services, and care navigation designed for large self-insured employers. It signals a shift toward more comprehensive, scalable employer health solutions.
Dr. Priya Nandakumar
Jan 31, 2026The health technology landscape entered 2026 with vigor, seen through four notable funding announcements that signal robust investor confidence. These funding rounds underpin developments in digital health, telemedicine, and biotechnology, marking an exciting chapter for healthcare innovation and investment.
Daniel Cho
Jan 29, 2026AstraZeneca continues to establish its footprint as a prolific investor in China’s biotech arena. This substantial capital infusion, following a recent $630 million commitment for full rights to AbelZeta’s cancer cell therapy, signals a robust strategic focus on advancing cell therapies and radiopharmaceutical technologies within the Chinese market.
Sophia Reynolds
Jan 29, 2026With growing awareness about the importance of lung health amid environmental challenges and respiratory concerns, Climatic's innovative inhalant product aims to establish a new category in preventive lung care. The company's recent funding underscores investor confidence in lung wellness solutions targeting proactive daily use.
Emily CarterMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.